This site is intended for healthcare professionals

The Lancet publishes pivotal Libtayo data showing extended overall survival in patients with first-line advanced NSCLC with PD-L1 expression of greater than 50%.- Sanofi + Regeneron.

Read time: 2 mins
Last updated:28th Jun 2021
Published:13th Feb 2021
Condition: Non Small Cell Lung Cancer
Type: drug
Register for free access to this exclusive healthcare learning resource

Why sign up with Medthority?

Develop your knowledge with our disease and condition focused Learning Zones

Access content from credible sources, including expert-led commentary, videos, podcasts, and webinars as well as clinical trials, treatment information and guidelines 

Personalised dashboard providing updates and recommendations for content within your areas of interest